Improving cytokine-induced killer cell expansion using a gas-permeable culture method for clinical-scale production
Overview
This paper compares CIK cell expansion in G-Rex® devices vs standard plates. G-Rex® 24-well and 6-well plates were used. G-Rex® resulted in significantly higher expansion and IFN-g secretion, supporting clinical-scale production.
What this paper found
Expanding cytokine-induced killer (CIK) cells in a gas-permeable G-Rex® plate produced more cells than a conventional 24-well plate, with similar phenotype and cytotoxicity. From 1 × 10^6 PBMCs per well (three healthy donors), 14-day G-Rex® 24-well cultures reached 110 × 10^6 total cells and 17 × 10^6 NK-T cells, versus 73 × 10^6 and 9 × 10^6 in standard plates, and secreted more IFN-γ. Cell subsets, activation markers and killing of K562 and Kasumi leukemia cells did not differ significantly. Seeding 30 × 10^6 PBMCs in a G-Rex® 6-well plate yielded over 1 × 10^9 cells per run (mean 5.1 × 10^9) in 14 days. A GMP donor-derived product given to a patient with AML relapsed after allogeneic transplant was followed by 2 years of complete remission.
Note: Clinical activity is described in a single patient treated on a compassionate-use basis rather than in a clinical trial; the bench comparison used cells from three healthy donors.
The gas-permeable culture method could expand cultured CIK cells in all samples to more than 1 × 10^9 cells from only 30 × 10^6 PBMCs after 14 days. — Supannikar Tawinwung, Suparat Tudsamran, Rattapoom Thaiwong, Thiti Asawapanumas, Kitsada Wudhikarn, Chantiya Chanswangphuwana, Nattiya Hirankarn, Udomsak Bunworasate, Koramit Suppipat, Asian Pacific Journal of Allergy and Immunology
Study details
- Authors
- Supannikar Tawinwung, Suparat Tudsamran, Rattapoom Thaiwong, Thiti Asawapanumas, Kitsada Wudhikarn, Chantiya Chanswangphuwana, Nattiya Hirankarn, Udomsak Bunworasate, Koramit Suppipat
- Institution
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand · Clinical Excellence Center for Comprehensive Cancer, King Chulalongkorn Memorial Hospital, Bangkok, Thailand · Division of Hematology and Research Unit in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand · Cancer Immunotherapy Excellence Center, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand · Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Chulalongkorn University, Bangkok, Thailand · Department of Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand · Cellular Immunotherapy Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- Journal
- Asian Pacific Journal of Allergy and Immunology
- Year
- 2022
- PMID / PMC
- PMID: 36592164
- G-Rex® model(s)
- G-Rex®24 Well Plate, G-Rex®6 Well Plate
- Cell type(s)
- Other
- Application area
- Hematologic malignancy
- Study phase
- Preclinical
How G-Rex® was used
PBMCs were seeded in a G-Rex® 24-well plate (2 cm² per well) at 1 × 10^6 cells in 8 mL of medium with IFN-γ, then given anti-CD3 and IL-2, and grown for 14 days with one partial medium change on day 7, alongside a conventional 24-well plate. For clinical-scale production, 5 × 10^6 PBMCs per well in 30 mL were seeded across a G-Rex® 6-well plate (10 cm² per well; 30 × 10^6 cells in total) and cultured for 14 days. The same G-Rex® 6-well protocol was used under GMP to make a 3.6 × 10^9-cell donor CIK product for a patient with relapsed AML.
Note: In the G-Rex® 24-well arm, IL-2 was added every 3 to 4 days, but the medium was exchanged only once, on day 7, during the 14-day culture.
Explore related
Full citation
Tawinwung S, Tudsamran S, Thaiwong R, et al. Improving cytokine-induced killer cell expansion using a gas-permeable culture method for clinical-scale production. Asian Pac J Allergy Immunol. 2025;43(3):673-684.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.